Patents Assigned to Lankenau Institute for Medical Research
  • Patent number: 11992532
    Abstract: Disclosed herein are PEG-DPCA conjugates having multiple hydrophobic DPCA groups at one or both terminal ends of a PEG compound and compositions thereof and methods of using thereof for tissue regeneration and/or cellular repair (e.g., wound healing).
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 28, 2024
    Assignees: The Regents of the University of California, Lankenau Institute for Medical Research
    Inventors: Phillip B. Messersmith, Jing Cheng, Ellen Heber-Katz
  • Patent number: 11946074
    Abstract: Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with in a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, they function as fusion partners to create hybridoma cells. The cells can be designed to bind a secreted targeted protein, e.g., a secreted antibody, to the cell surface via an immune complex formed by the Anchor-Linker and permit the identification of the existence, antigen specificity, and antigen binding affinity, titer, amount, or biological activity of the target protein. In certain embodiments, the Linker is of a species heterologous to the species of the Anchor; and the target protein is of a species heterologous to the Linker and to the Anchor.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 2, 2024
    Assignee: Lankenau Institute for Medical Research
    Inventors: Scott K. Dessain, Rama Devudu Puligedda
  • Publication number: 20240084002
    Abstract: Compositions and methods for treating a retinopathy or inhibiting pathologic neovascularization in a subject are provided herein. In one embodiment, the method includes ablating or inhibiting IDO-dependent vascularizing cells (IDVCs) in the eye of the subject. Various methods of inhibiting or ablating IDVCs are described, including inhibiting IDO1 and/or integrated response nodes.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 14, 2024
    Applicants: LANKENAU INSTITUTE FOR MEDICAL RESEARCH, DUET THERAPEUTICS, INC.
    Inventors: Alexander J. Muller, Arpita Mondal, Souvik Dey, Simon Tomlinson, Lisa Laury-Kleintop
  • Publication number: 20240060043
    Abstract: Fusion proteins, comprising at least one single chain antibody fragment (scFV), and a cancer antigen or marker, or a fragment thereof are provided. The scFV is capable of selectively binding to a cytokine released by chimeric antigen receptor (CAR) expressing cell such as interferon gamma (IFN-?) or tumor necrosis factor alpha (TNF-?). The cancer antigen or marker may comprise the extracellular domain of CD19. Methods for isolating or purifying CAR expressing cells using fusion proteins are provided.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 22, 2024
    Applicants: Villanova University, Lankenau Institute for Medical Research
    Inventors: William Joseph Kelly, III, Justin Thomas Fisher, Scott Kendall Dessain
  • Patent number: 11897942
    Abstract: The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 13, 2024
    Assignees: Temple University—Of The Commonwealth System of Higher Education, LANKENAU INSTITUTE OF MEDICAL RESEARCH
    Inventors: Cagla Tukel Wilson, Scott Dessain
  • Publication number: 20230301967
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.
    Type: Application
    Filed: January 23, 2023
    Publication date: September 28, 2023
    Applicant: Lankenau Institute for Medical Research
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 11761949
    Abstract: A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical anesthetic.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: September 19, 2023
    Assignee: Lankenau Institute for Medical Research
    Inventor: Margaretha Wallon
  • Patent number: 11564906
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: January 31, 2023
    Assignee: Lankenau Institute for Medical Research
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 11564907
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: January 31, 2023
    Assignee: Lankenau Institute for Medical Research
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 11447568
    Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 20, 2022
    Assignee: Lankenau Institute for Medical Research
    Inventors: Arturo Bravo-Nuevo, George C. Prendergast
  • Patent number: 11376236
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: July 5, 2022
    Assignee: Lankenau Institute for Medical Research
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 11345747
    Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 31, 2022
    Assignee: Lankenau Institute for Medical Research
    Inventors: Thomas Sunil, James Mullin, George C. Prendergast
  • Patent number: 10525035
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 7, 2020
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 10494424
    Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: December 3, 2019
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Sunil Thomas, James Mullin, George C. Prendergast
  • Patent number: 9879092
    Abstract: Anti-RhoB antibodies, compositions comprising the same, and methods for the treatment of autoimmune and inflammatory diseases using the anti-RhoB antibodies are disclosed.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: January 30, 2018
    Assignee: Lankenau Institute for Medical Research
    Inventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
  • Publication number: 20180009882
    Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 11, 2018
    Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Sunil Thomas, James Mullin, George C. Prendergast
  • Patent number: 9766226
    Abstract: Compositions and methods for the measuring toxicity, antioxidant capacity, and oxidative stress are provided.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: September 19, 2017
    Assignee: Lankenau Institute for Medical Research
    Inventor: Iraimoudi S. Ayene
  • Patent number: 9522164
    Abstract: Compositions and methods for the treatment of cancer are provided.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: December 20, 2016
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Iraimoudi S. Ayene, George C. Prendergast
  • Patent number: 9446007
    Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: September 20, 2016
    Assignees: Dynamis Therapeutics, Inc., Lankenau Institute for Medical Research
    Inventors: Annette Tobia, Arturo Bravo Nuevo, Lisa Laury-Kleintop
  • Patent number: RE49708
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 24, 2023
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: George C. Prendergast, Richard Metz